Pacific Biosciences of California, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Pacific Biosciences of California, Inc. (PACB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $800.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-25
- Pacific Biosciences of California, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $800.00K, a 90.91% decline from fiscal 2023.
- Pacific Biosciences of California, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $8.80M, a 76.00% increase from fiscal 2022.
- Pacific Biosciences of California, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $5.00M, a 96.58% decline from fiscal 2021.
- Pacific Biosciences of California, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $146.10M, a 131.54% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2024-12-31 | $800.00K 10-K · filed 2026-02-25 |
| 2023-12-31 | $8.80M 10-K · filed 2026-02-25 |
| 2022-12-31 | $5.00M 10-K · filed 2025-03-17 |
| 2021-12-31 | $146.10M 10-K · filed 2024-02-28 |
| 2020-12-31 | $63.10M 10-K · filed 2023-02-28 |
| 2019-12-31 | $2.60M 10-K · filed 2020-02-28 |
| 2018-12-31 | $5.30M 10-K · filed 2020-02-28 |
| 2017-12-31 | $1.70M 10-K · filed 2020-02-28 |
| 2016-12-31 | $4.70M 10-K · filed 2019-02-26 |
| 2015-12-31 | $3.50M 10-K · filed 2018-02-26 |
| 2014-12-31 | $2.00M 10-K · filed 2017-03-06 |
| 2013-12-31 | $500.00K 10-K · filed 2016-03-11 |
| 2012-12-31 | $700.00K 10-K · filed 2015-03-12 |
| 2011-12-31 | $11.00M 10-K · filed 2014-03-14 |
| 2010-12-31 | $6.00M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |